Navigation Links
Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
Date:1/30/2009

NEWARK, Del., Jan. 30 /PRNewswire/ -- The Center for Molecular Biology (CMB) has received an $8.7 million grant from the Bill & Melinda Gates Foundation to support continued development of an avian influenza vaccine that uses transient plant-based technology. CMB will develop vaccines against highly pathogenic avian influenza viruses of H5N1 subtype, and work to advance promising candidates into clinical trials.

Dr. Vidadi Yusibov, CMB's Executive Director said, "CMB's vaccine technology has the potential to revolutionize how vaccines are manufactured, allowing for a more rapid and affordable response to pandemic flu threats."

"It is essential that new vaccines reach the people who need them most," said Doug Holtzman, Senior Program Officer for the Bill & Melinda Gates Foundation. "If successful, this project could help developing countries respond quickly to outbreaks of influenza and other infectious diseases to significantly limit their impact on vulnerable populations."

CMB's platform provides a new alternative to traditional vaccine production, with improved speed, surge capacity, and cost efficiency. The technology has also earned support from the Defense Advanced Research Projects Agency (DARPA) to continue developing the technology and establish it as a platform for accelerated manufacturing pharmaceuticals. The transient plant- based expression technology is licensed by CMB from its partner, iBioPharma, Inc.

About Fraunhofer Center for Molecular Biotechnology

Fraunhofer CMB's mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. CMB's technology provides a safe, rapid and economical alternative for vaccine production. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at www.fraunhofer-cmb.org

Fraunhofer CMB is one of six Fraunhofer USA research centers. Fraunhofer USA, Inc. is a non-profit research and development corporation, with headquarters in Michigan. It operates through technology centers that are partnered with major research universities in the United States and also with parent research institutes in Germany. Fraunhofer USA is a wholly-owned subsidiary of Fraunhofer Gesellschaft which promotes and undertakes applied research in an international context, of direct utility to private and public enterprise and of wide benefit to society as a whole.

    Contact:
    Dr. Vidadi Yusibov, Executive Director
    Fraunhofer CMB
    (302) 369-3034

'/>"/>
SOURCE Fraunhofer Center for Molecular Biotechnology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fraunhofer and Boston University Hosted Prestigious SME Tour
2. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
3. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
4. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Lafayette General Medical Center is the First Hospital in Louisiana to Use Genetic-Based Technology to Test for Respiratory Disease
7. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
8. NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas
9. BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative
10. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
11. St. Josephs Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
Breaking Biology News(10 mins):